Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,597,954 papers from all fields of science
Search
Sign In
Create Free Account
Vistusertib
Known as:
Benzamide, 3-(2,4-Bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-
An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
AZD2014
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Vistusertib for ER-Positive Breast Cancer
W. Gradishar
2019
Corpus ID: 213609176
The PI3K-AKT-mTOR pathway is the subject of intense clinical investigation, particularly in ER-positive breast cancer. Mutations…
Expand
Review
2019
Review
2019
Review for "A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL"
C. Cheah
2019
Corpus ID: 201179859
2018
2018
Olaparib Plus Vistusertib Promising in Early Trial of Endometrial, Other Cancers
D. Levitan
2018
Corpus ID: 146049048
The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial…
Expand
2018
2018
Abstract P1-03-04: Role of PTEN and BRCA1 as determinants of synergy for the combination of vistusertib with carboplatin and olaparib in TNBC
J. Carlson
,
M. O'Connor
,
P. De
,
N. Dey
,
B. Leyland-Jones
2018
Corpus ID: 80224551
2017
2017
Vistusertib Fares Worse Than Everolimus in Breast Cancer Combination
D. Levitan
2017
Corpus ID: 217188643
Adding vistusertib to fulvestrant failed to demonstrate a benefit over everolimus in patients with ER-positive advanced or…
Expand